Choosing between Bristol Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) means deciding whether you prefer a pure-play pharmaceutical company trading at a deep discount or a diversified giant with higher growth.
While both operate within the same broader sector, their business models differ significantly. Bristol Myers focuses heavily on drug development for serious diseases, while Johnson & Johnson splits its attention between medicine and medical devices. Let's compare them and weigh their specific risks and financial health.
Bristol Myers operates as a major player in the pharmaceutical stocks **** e, focusing on oncology, hematology, and immunology. The company sells its innovative medicines primarily to wholesalers and specialty pharmacies, relying on established distribution channels for top products like Opdivo and Eliquis. Key commercial alliances with Merck (NYSE:MRK) and BioNTech (NASDAQ:BNTX) help Bristol Myers expand its reach in specialized therapeutic areas.
In fiscal 2025, revenue reached nearly $48.2 billion, reflecting a slight decrease of approximately 0.2% compared to the previous year. The company reported net income of roughly $7.1 billion during this period, resulting in a net margin of approximately 14.6%. This was a significant recovery from the prior fiscal year, when Bristol Myers recorded a substantial net loss following specific business shifts.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6. This figure, which compares total debt to the value of shareholder equity, suggests a higher reliance on borrowed funds. The current ratio, which measures the company's ability to cover short-term debts with current **** ets, is approximately 1.3, while free cash flow reached nearly $12.8 billion.
While both operate within the same broader sector, their business models differ significantly. Bristol Myers focuses heavily on drug development for serious diseases, while Johnson & Johnson splits its attention between medicine and medical devices. Let's compare them and weigh their specific risks and financial health.
Bristol Myers operates as a major player in the pharmaceutical stocks **** e, focusing on oncology, hematology, and immunology. The company sells its innovative medicines primarily to wholesalers and specialty pharmacies, relying on established distribution channels for top products like Opdivo and Eliquis. Key commercial alliances with Merck (NYSE:MRK) and BioNTech (NASDAQ:BNTX) help Bristol Myers expand its reach in specialized therapeutic areas.
In fiscal 2025, revenue reached nearly $48.2 billion, reflecting a slight decrease of approximately 0.2% compared to the previous year. The company reported net income of roughly $7.1 billion during this period, resulting in a net margin of approximately 14.6%. This was a significant recovery from the prior fiscal year, when Bristol Myers recorded a substantial net loss following specific business shifts.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6. This figure, which compares total debt to the value of shareholder equity, suggests a higher reliance on borrowed funds. The current ratio, which measures the company's ability to cover short-term debts with current **** ets, is approximately 1.3, while free cash flow reached nearly $12.8 billion.
3 months ago
